Acarix AB
7AC
Company Profile
Business description
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). The CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics.
Contact
Hyllie Boulevard 34, 5TR
c/o Regus Hyllie
Malmo215 32
SWESector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
8
Stocks News & Analysis
stocks
Moated ASX player’s future growth prospects look solid
We expect the strong earnings momentum at this company to continue, with shares looking fairly valued.
stocks
Ask the analyst: Can this genius product create the next ASX software king?
SiteMinder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,107.90 | 14.60 | -0.16% |
| CAC 40 | 7,854.61 | 36.39 | 0.47% |
| DAX 40 | 23,674.53 | 315.35 | 1.35% |
| Dow JONES (US) | 46,142.42 | 124.10 | 0.27% |
| FTSE 100 | 9,228.11 | 32.45 | 0.35% |
| HKSE | 26,663.80 | 225.29 | 0.85% |
| NASDAQ | 22,470.72 | 209.40 | 0.94% |
| Nikkei 225 | 45,743.57 | 841.30 | 1.87% |
| NZX 50 Index | 13,221.49 | 13.40 | -0.10% |
| S&P 500 | 6,631.96 | 31.61 | 0.48% |
| S&P/ASX 200 | 8,816.00 | 32.50 | -0.37% |
| SSE Composite Index | 3,864.81 | 11.53 | -0.30% |